SILK ROAD MEDICAL, INC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.5 USD | +1.38% |
|
-4.61% | +56.72% |
| Apr. 30 | Transcript : Silk Road Medical, Inc, Q1 2024 Earnings Call, Apr 30, 2024 | |
| Apr. 30 | Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q1 Revenue $48.5M, vs. Street Est of $44.7M | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 197M | Sales 2025 * | 218M | Capitalization | 759M |
|---|---|---|---|---|---|
| Net income 2024 * | -54M | Net income 2025 * | -52M | EV / Sales 2024 * | 3.79 x |
| Net cash position 2024 * | 11.13M | Net cash position 2025 * | 41.33M | EV / Sales 2025 * | 3.28 x |
| P/E ratio 2024 * |
-14.1
x | P/E ratio 2025 * |
-14.7
x | Employees | 474 |
| Yield 2024 * |
0.66% | Yield 2025 * |
-
| Free-Float | 94.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on Silk Road Medical, Inc
More recommendations
More press releases
| 1 day | -6.47% | ||
| 1 week | -4.61% | ||
| Current month | -1.08% | ||
| 1 month | +9.70% | ||
| 3 months | +15.63% | ||
| 6 months | +139.48% | ||
| Current year | +56.72% |
1 week
19.21
21.24
1 month
16.4021.24
Current year
11.0522.52
1 year
6.0837.99
3 years
6.0867.49
5 years
6.0875.80
10 years
6.0875.80
| Managers | Title | Age | Since |
|---|---|---|---|
Charles McKhann
CEO | Chief Executive Officer | 55 | Nov. 01 |
Lucas Buchanan
DFI | Director of Finance/CFO | 46 | 09-07-31 |
William Whealon
CTO | Chief Tech/Sci/R&D Officer | - | 20-09-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Don Zurbay
BRD | Director/Board Member | 56 | 18-03-25 |
Kevin Ballinger
BRD | Director/Board Member | 51 | 20-12-02 |
Jack Lasersohn
CHM | Chairman | 70 | 07-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.06% | 0 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 19.23 | -6.47% | 630 114 |
| 24-05-07 | 20.56 | -1.63% | 518,564 |
| 24-05-06 | 20.9 | +3.06% | 536,200 |
| 24-05-03 | 20.28 | +7.30% | 644,255 |
| 24-05-02 | 18.9 | -6.25% | 723,524 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
19.23
USD
Average target price
19
USD
Spread / Average Target
-1.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +56.72% | 759M | |
| -4.66% | 183B | |
| -1.01% | 108B | |
| -4.20% | 67.51B | |
| +2.68% | 50.67B | |
| +9.12% | 44.7B | |
| +2.41% | 40.95B | |
| +4.13% | 26.71B | |
| +3.31% | 26.8B | |
| +12.66% | 24.62B |
- Stock Market
- Equities
- SILK Stock